康哲药业（00867）：重磅品种芦可替尼获批上市，未来增长可期

Investment Rating - The report assigns a positive outlook on China Medical System Holdings, particularly highlighting the approval of ruxolitinib cream as a significant growth opportunity for the company [1][8]. Core Insights - Ruxolitinib cream has been approved by the NMPA for treating non-segmental vitiligo in patients aged 12 and above, which is expected to drive substantial revenue growth [1][8]. - The management anticipates that ruxolitinib cream will generate revenue of at least CNY 500 million in 2026, doubling in 2027, with peak revenue expectations of no less than CNY 6 billion within 4-5 years [3][11]. - The company has initiated pilot applications of ruxolitinib cream in Hainan, with over 7,700 patients already using the product before its official approval [2][10]. Summary by Sections Product Approval and Market Potential - Ruxolitinib cream, developed as a selective JAK1/JAK2 inhibitor, has received approval for treating non-segmental vitiligo, a condition affecting approximately 10.3 million people in China [1][9]. - The cream is expected to fill a market gap due to the limitations of existing therapies for vitiligo, which include adverse effects and limited efficacy [4][12]. Sales and Marketing Strategy - The company plans to focus on DTP pharmacies and online platforms for distribution, having already established agreements with JD Health and Ali Health [2][10]. - Management is preparing for participation in the 2026 National Reimbursement Drug List negotiations to facilitate broader access to the product [2][10]. Revenue Projections - The revenue guidance for ruxolitinib cream includes expectations of over CNY 5 billion from vitiligo indications and over CNY 1 billion from atopic dermatitis indications [3][11]. - The pricing strategy indicates that the official listed price will be lower than the pilot price of CNY 6,800 per tube [3][11]. Future Developments - The report suggests continued monitoring of ruxolitinib cream's application for mild-to-moderate atopic dermatitis, with an expected marketing application submission in the near future [4][13].